Melanoma & Skin Cancer Trials
Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY17022
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGF- Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-Driven Advanced Solid Tumors
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFB. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
Study InformationSTUDY23589
A Phase 1 Open Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
To assess the efficacy of ABBV-400 in each solid tumor indication, including advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC and HNSCC. To characterize the safety and tolerability of ABBV-400 as monotherapy in advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC, and HNSCC.
Study InformationSTUDY23849
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a study. Phase 1 adopts an accelerated titration at first dose level followed with classic "3+3" design to identify the MTD and/or RP2D. Phase 2a is a dose expansion phase to confirm the safety, tolerability and explore efficacy in selected malignant solid tumors treated with DB-1311 as monotherapy.
Study InformationSTUDY25269
A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors
To determine the safety profile, and tolerability of BNT317 in patients with advanced solid tumors. To determine the MTD or the RP2D of BNT317 in patients with advanced solid tumors.
Study InformationSTUDY26334
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
To determine the RP2D of DB-1311 in combination with BNT327 by assessing the safety and tolerability in targeted participant populations. To determine the RP2D of DB-1311 in combination with DB-1305 by assessing the safety and tolerability in targeted participant populations.
Study InformationSTUDY26821
A Phase 1, First-in-Human, Open-label, Multicenter Study of JZP898 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors
To determine the MonoRD and/or MTD (or highest cleared DL) of JZP898 as well as the CombiRD of JZP898 in combination with pembrolizumab. To characterize the safety and tolerability profile of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab.
Study InformationSTUDY28732
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
To compare PFS for brenetafusp + nivolumab to nivolumab regimens.
Study InformationSTUDY29475
A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients
Patient-Reported Outcome (PRO) Component [Time Frame: (FACT-M) baseline 4 months 8 months 12 months 16 months 20 months 24 months] The patient reported outcomes (PRO) in this study include a Geriatric Assessment (GA) and the FACT-M Quality of Life (QOL). The National Comprehensive Cancer Network (NCCN) guidelines advocate geriatric assessment (GA) for older patients with cancer to identify health status issues that increase the risk of adverse outcomes. A GA evaluates comorbidity, functional status, physical performance, cognitive ability, psychological status, medications and social support with standardized tools that predict morbidity and mortality in community-dwelling vulnerable older adults. Benefits of GA in community-dwelling vulnerable older adults include prevention of geriatric syndromes, recognition of cognitive deficits, addressing geriatric abnormalities detected by the assessment to prevent hospitalizations and nursing home admissions, and overall improvement of quality of life.
Study Information